서보메드(CRVO)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $2.73 (-6.83%), 시가총액 $0.03B, 52주 범위 $2.89 ~ $10.69.
CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. The company is developing neflamapimod, an orally administered small molecule drug that crosses the blood"brain barrier and inhibits the enzyme p38a. Neflamapimod has the potential to reverse synaptic dysfunction, improve neuron health, and slow or prevent disease progression. Neflamapimod is currently in clinical development for the treatment of dementia with Lewy bodies, non-fluent variant primary progressive aphasia, amyotrophic lateral sclerosis, and amyotrophic lateral sclerosis. CervoMed Inc. was founded in 2010 and is headquartered
서보메드의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackQuant에서 실시간으로 확인할 수 있습니다.
서보메드의 현재 주가는 $2.73 (-6.83%)입니다. BlackQuant에서 실시간 시세와 차트를 확인할 수 있습니다.
서보메드의 시가총액은 약 $0.03B입니다.
CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. The company is developing neflamapimod, an o